Marker Type of marker Source Stem-like characteristics Reference
Side Population Biochemical Mouse ovarian cancer cell lines Primary ovarian xenografts cell lines Human ovarian cancer cell line Patients ascites Tumorigenicity, chemoresistance, asymmetric division Tumorigenicity, high proliferation rate, low apoptotic events Tumorigenicity, chemoresistance, low apoptotic events, clonogenicity, high expression of stemness genes Tumorigenicity, chemoresistance, low apoptotic events [20] [79] [80], [81] [81]
ALDH Biochemical Human ovarian cancer cell lines, ovarian tumor xenografts Tumorigenicity, chemoresistance, self-renewal [68]
CD133 Surface marker Human ovarian cancer cell lines Primary ovarian tumors Primary ovarian xenografts Tumorigenicity, chemoresistance, asymmetric division, self-renewal Clonogenicity, high proliferation rate Tumorigenicity [18] [72] [73]
CD117 Surface marker Primary ovarian tumor xenografts Tumorigenicity, chemoresistance, self-renewal [78]
CD24 Surface marker Primary ovarian cell line  Chemoresistance, high expression of stemness genes, self-renewal [26]
ALDH+/CD133+ Biochemical+ urface marker Human ovarian cancer cell lines, patient tumors Primary ovarian tumors and ascites Tumorigenicity, chemoresistance, spheres formation, angiogenic capacity Tumorigenicity, spheres formation [74] [22]
ALDH+/CD44+ Biochemical+ surface marker Human ovarian cancer cell lines  Chemoresistance [75]
CD44+/CD24- Surface marker Human ovarian cancer cell lines Human ovarian cancer cell lines Tumorigenicity, chemoresistance, self-renewal, spheres formation Chemoresistance, clonogenicity [76] [77]
CD44+/Myd88+ Surface marker+ cytoplasmatic adaptor protein Primary ovarian tumors and ascites Tumorigenicity, chemoresistance, low apoptotic events, self-renewal,       spheres formation [19]
CD44+/CD117+ Surface marker Primary ovarian tumor spheroids Tumorigenicity, chemoresistance, high expression of stemness markers,       self-renewal, spheres formation [24]
Table 1: Identification of ovarian cancer stem cell markers.